Ignite Creation Date:
2024-05-05 @ 5:33 PM
Last Modification Date:
2024-10-26 @ 9:33 AM
Study NCT ID:
NCT00481962
Status:
COMPLETED
Last Update Posted:
2009-09-28
First Post:
2007-05-31
Brief Title:
Health Economic Assessment of Tygacil in the Treatment of Secondary Peritonitis in Intensive Care Units ICUs
Sponsor:
Wyeth is now a wholly owned subsidiary of Pfizer
Organization:
Wyeth is now a wholly owned subsidiary of Pfizer
Study Overview
Official Title:
Health Economic Assessment of Tygacil in the Treatment of Secondary Peritonitis in Intensive Care Units
Status:
COMPLETED
Status Verified Date:
2009-09
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The main goals of the study are Assessment of Tygacils cost-effectiveness Process cost analysis from a hospital perspective including length of stay treatment costs side effect management costs costs of monitoring costs of diagnostic procedures cost of care TISS 10 score etc Efficacy of Tygacil under usual care conditions cure rate
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None